Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) is now available.
Sihuan Pharmaceutical Holdings Group Ltd. has made an equity investment in Swiss company Suisselle SA to strengthen its position in the global medical aesthetic market. This investment grants Sihuan permanent exclusive distribution rights for Suisselle’s CELLBOOSTER® skin booster products in China and enhances their collaboration to promote medical aesthetic products in Europe and other markets. The move aligns with Sihuan’s globalization strategy, complementing its previous acquisition of Genesis Biosystems in the U.S., and aims to create long-term sustainable value for shareholders.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd. operates in the pharmaceutical industry, focusing on medical aesthetics. The company is involved in the research, development, production, and sales of medical aesthetic products, with a strategic emphasis on global market expansion.
YTD Price Performance: 150.38%
Average Trading Volume: 87,986,735
Technical Sentiment Signal: Buy
Current Market Cap: HK$15.3B
For detailed information about 0460 stock, go to TipRanks’ Stock Analysis page.